Reported 4 days ago
Sangamo Therapeutics experienced a drastic drop of over 50% in its stock value following Pfizer's decision to terminate their collaboration on a hemophilia treatment. The companies were developing a gene therapy for adults with severe hemophilia A, and despite disappointing news, Sangamo plans to seek a new partner to continue the drug's development and commercialization.
Source: YAHOO